TrialLeukemia2021
Lomustine is beneficial to older AML with ELN2017 adverse risk profile and intermediate karyotype: a FILO study.
Laetitia Largeaud et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it
TrialLeukemia2021
Laetitia Largeaud et al.PubMed ↗Publisher ↗
No numbers read from the abstract.